Summary

The global next generation diabetes therapy and drug delivery market was valued at $7,080.6 million in 2020 and is projected to reach $28,044.23 million by 2030, registering a CAGR of 14.28% from 2021 to 2030. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. These products help in the management of the blood glucose level of diabetic patient in minimally invasive manner. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients. It is a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improve management of blood sugar level and reduces the risk of any diabetic-related complications.
The main factors that drive the growth of the next generation diabetes therapy and the drug delivery market include, the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure.
In addition, rise in incidences of diabetes globally and increase in the disposable income among the diabetic patients, further supplement the global next generation diabetes therapy and drug delivery market growth.
Conversely lack of awareness, cost restrains in the developing regions, and less variability in products are expected to obstruct the growth of the market during forecast years. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period.
The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographics, it is bifurcated into adult population (>14 years) and child population (≤14 years). By indication, it is divided into type 1 diabetes and type 2 diabetes. On the basis of end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key market players profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson.
KEY BENEFITS FOR STAKEHOLDERS
· The study provides an in-depth analysis of the global next generation diabetes therapy and drug delivery market along with the current trends and future estimations to elucidate the imminent investment pockets.
· A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
· Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
· Extensive analysis of the key segments of the industry helps to understand the application and products of next generation diabetes therapy and drug delivery used across the globe.
· Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

ページTOPに戻る

Table of Contents

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Inhalable Insulin
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oral Insulin
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Insulin Patches
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 CGM Systems
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Artificial Pancreas
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC
5.1 Overview
5.1.1 Market size and forecast
5.2 Adult Population (>14years)
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Child Population (14years)
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Type 1 Diabetes
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Type 2 Diabetes
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Diagnostic/Clinics
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 ICUs
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Home Healthcare
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
CHAPTER 8: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product
8.2.3 North America Market size and forecast, by Demographic
8.2.4 North America Market size and forecast, by Indication
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product
8.2.6.1.2 Market size and forecast, by Demographic
8.2.6.1.3 Market size and forecast, by Indication
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product
8.2.6.2.2 Market size and forecast, by Demographic
8.2.6.2.3 Market size and forecast, by Indication
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product
8.2.6.3.2 Market size and forecast, by Demographic
8.2.6.3.3 Market size and forecast, by Indication
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product
8.3.3 Europe Market size and forecast, by Demographic
8.3.4 Europe Market size and forecast, by Indication
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product
8.3.6.1.2 Market size and forecast, by Demographic
8.3.6.1.3 Market size and forecast, by Indication
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product
8.3.6.2.2 Market size and forecast, by Demographic
8.3.6.2.3 Market size and forecast, by Indication
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 U.K.
8.3.6.3.1 Market size and forecast, by Product
8.3.6.3.2 Market size and forecast, by Demographic
8.3.6.3.3 Market size and forecast, by Indication
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product
8.3.6.4.2 Market size and forecast, by Demographic
8.3.6.4.3 Market size and forecast, by Indication
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product
8.3.6.5.2 Market size and forecast, by Demographic
8.3.6.5.3 Market size and forecast, by Indication
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product
8.3.6.6.2 Market size and forecast, by Demographic
8.3.6.6.3 Market size and forecast, by Indication
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product
8.4.3 Asia-Pacific Market size and forecast, by Demographic
8.4.4 Asia-Pacific Market size and forecast, by Indication
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Market size and forecast, by Product
8.4.6.1.2 Market size and forecast, by Demographic
8.4.6.1.3 Market size and forecast, by Indication
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 Japan
8.4.6.2.1 Market size and forecast, by Product
8.4.6.2.2 Market size and forecast, by Demographic
8.4.6.2.3 Market size and forecast, by Indication
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 India
8.4.6.3.1 Market size and forecast, by Product
8.4.6.3.2 Market size and forecast, by Demographic
8.4.6.3.3 Market size and forecast, by Indication
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 Australia
8.4.6.4.1 Market size and forecast, by Product
8.4.6.4.2 Market size and forecast, by Demographic
8.4.6.4.3 Market size and forecast, by Indication
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product
8.4.6.5.2 Market size and forecast, by Demographic
8.4.6.5.3 Market size and forecast, by Indication
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product
8.4.6.6.2 Market size and forecast, by Demographic
8.4.6.6.3 Market size and forecast, by Indication
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product
8.5.3 LAMEA Market size and forecast, by Demographic
8.5.4 LAMEA Market size and forecast, by Indication
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product
8.5.6.1.2 Market size and forecast, by Demographic
8.5.6.1.3 Market size and forecast, by Indication
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product
8.5.6.2.2 Market size and forecast, by Demographic
8.5.6.2.3 Market size and forecast, by Indication
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product
8.5.6.3.2 Market size and forecast, by Demographic
8.5.6.3.3 Market size and forecast, by Indication
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product
8.5.6.4.2 Market size and forecast, by Demographic
8.5.6.4.3 Market size and forecast, by Indication
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Abbott laboratories
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Dexcom, Inc
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Eli Lilly and Company
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Glysens Incorporated
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Johnson & Johnson
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 MannKind Corporation
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Medtronic plc
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Novo Nordisk A/S
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 Sanofi S.A.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Senseonics Holdings, Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INHALABLE INSULIN, BY REGION , 2020-2030,($MILLION)
TABLE 3. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INHALABLE INSULIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ORAL INSULIN, BY REGION , 2020-2030,($MILLION)
TABLE 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ORAL INSULIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INSULIN PATCHES, BY REGION , 2020-2030,($MILLION)
TABLE 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INSULIN PATCHES BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CGM SYSTEMS, BY REGION , 2020-2030,($MILLION)
TABLE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CGM SYSTEMS BY COUNTRY, 2020-2030,($MILLION)
TABLE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ARTIFICIAL PANCREAS, BY REGION , 2020-2030,($MILLION)
TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ARTIFICIAL PANCREAS BY COUNTRY, 2020-2030,($MILLION)
TABLE 12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ADULT POPULATION (>14YEARS), BY REGION , 2020-2030,($MILLION)
TABLE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ADULT POPULATION (>14YEARS) BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CHILD POPULATION (14YEARS), BY REGION , 2020-2030,($MILLION)
TABLE 16. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CHILD POPULATION (14YEARS) BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 1 DIABETES, BY REGION , 2020-2030,($MILLION)
TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 1 DIABETES BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 2 DIABETES, BY REGION , 2020-2030,($MILLION)
TABLE 21. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 2 DIABETES BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 23. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR DIAGNOSTIC/CLINICS, BY REGION , 2020-2030,($MILLION)
TABLE 24. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET DIAGNOSTIC/CLINICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 25. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ICUS, BY REGION , 2020-2030,($MILLION)
TABLE 26. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ICUS BY COUNTRY, 2020-2030,($MILLION)
TABLE 27. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR HOME HEALTHCARE, BY REGION , 2020-2030,($MILLION)
TABLE 28. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET HOME HEALTHCARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 30. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 31. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 32. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 33. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 34. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 35. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 36. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 37. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 38. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 39. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 40. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 41. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 42. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 43. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 44. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 45. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 46. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 47. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 48. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 49. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 50. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 51. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 52. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 53. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 54. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 55. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 56. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 57. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 58. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 59. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 60. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 61. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 62. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 63. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 65. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 66. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 67. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 68. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 69. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 70. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 71. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 72. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 73. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 74. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 75. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 76. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 77. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 78. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 79. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 80. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 81. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 82. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 83. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 84. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 85. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 86. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 87. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 88. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 89. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 90. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 91. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 92. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 93. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 94. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 95. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 96. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 97. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 98. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 99. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 100. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 101. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 102. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 103. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 104. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 105. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 106. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
TABLE 107. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
TABLE 108. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 109. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 110. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 111. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 112. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 113. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 114. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 115. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 116. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 117. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 118. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 119. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 120. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 121. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 122. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 123. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
TABLE 124. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
TABLE 125. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
TABLE 126.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 127.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 128.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 129.ABBOTT LABORATORIES: NET SALES,
TABLE 130.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 131.DEXCOM, INC: COMPANY SNAPSHOT
TABLE 132.DEXCOM, INC: OPERATING SEGMENTS
TABLE 133.DEXCOM, INC: PRODUCT PORTFOLIO
TABLE 134.DEXCOM, INC: NET SALES,
TABLE 135.DEXCOM, INC: KEY STRATERGIES
TABLE 136.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 137.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 138.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 139.ELI LILLY AND COMPANY: NET SALES,
TABLE 140.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 141.GLYSENS INCORPORATED: COMPANY SNAPSHOT
TABLE 142.GLYSENS INCORPORATED: OPERATING SEGMENTS
TABLE 143.GLYSENS INCORPORATED: PRODUCT PORTFOLIO
TABLE 144.GLYSENS INCORPORATED: NET SALES,
TABLE 145.GLYSENS INCORPORATED: KEY STRATERGIES
TABLE 146.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 147.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 148.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 149.JOHNSON & JOHNSON: NET SALES,
TABLE 150.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 151.MANNKIND CORPORATION: COMPANY SNAPSHOT
TABLE 152.MANNKIND CORPORATION: OPERATING SEGMENTS
TABLE 153.MANNKIND CORPORATION: PRODUCT PORTFOLIO
TABLE 154.MANNKIND CORPORATION: NET SALES,
TABLE 155.MANNKIND CORPORATION: KEY STRATERGIES
TABLE 156.MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 157.MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 158.MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 159.MEDTRONIC PLC: NET SALES,
TABLE 160.MEDTRONIC PLC: KEY STRATERGIES
TABLE 161.NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 162.NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 163.NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 164.NOVO NORDISK A/S: NET SALES,
TABLE 165.NOVO NORDISK A/S: KEY STRATERGIES
TABLE 166.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 167.SANOFI S.A.: OPERATING SEGMENTS
TABLE 168.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 169.SANOFI S.A.: NET SALES,
TABLE 170.SANOFI S.A.: KEY STRATERGIES
TABLE 171.SENSEONICS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 172.SENSEONICS HOLDINGS, INC.: OPERATING SEGMENTS
TABLE 173.SENSEONICS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 174.SENSEONICS HOLDINGS, INC.: NET SALES,
TABLE 175.SENSEONICS HOLDINGS, INC.: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SEGMENTATION
FIGURE 2.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030
FIGURE 3.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY PRODUCT,2020(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INHALABLE INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INSULIN PATCHES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CGM SYSTEMS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ARTIFICIAL PANCREAS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 18.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY DEMOGRAPHIC,2020(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ADULT POPULATION (>14YEARS) NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHILD POPULATION (14YEARS) NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 21.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY INDICATION,2020(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF TYPE 1 DIABETES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF TYPE 2 DIABETES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 24.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY END USER,2020(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC/CLINICS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF ICUS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF HOME HEALTHCARE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
FIGURE 28.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY REGION,2020
FIGURE 29.U.S. NEXT GENERATION DIABETES